title: Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
abstract: Still no proof that saxagliptin prevents the clinical complications of diabetes, but an increase in hospitalisations for heart failure in a large trial in patients at high cardiovascular risk.
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D004151:Dipeptides / Q000009:adverse effects*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006760:Hospitalization; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; C502994:saxagliptin; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000218:Adamantane